Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Kadmon Holdings Inc.
DescriptionFusion protein inhibiting PD-L1 and IL-15
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) ; Interleukin-15 (IL-15)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today